Learn how to talk with patients who have major depressive disorder about antipsychotic treatment in a way that is clear and balanced and addresses patients’ potential concerns about taking antipsychotic medication.
The Journal of Clinical Psychiatry
Insights April 6, 2021
Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics
J Clin Psychiatry 2020;81(3):OT19037BR3
Vol 87 • 2026 • Number 1
Read the Current Issue
ASCP Corner
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
Original Research
How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?
Meta-Analysis
Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety
Original Research
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
Brief Report
Exercise Reduces Dysphoria in Clinical High-Risk for Psychosis: A Randomized Controlled Trial
Clinical and Practical Psychopharmacology
Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes
Related Articles
Insights
Measurement-Based Care for Depressive Disorders: Meta-Analysis of RCTs Shows Efficacy
May 17, 2022
Dr Lam explains in this video how for patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.
